Recent Updates
Recently added Catalysts
MDXG Negative Sentiment

MIMEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating MiMedx Group, Inc. on Behalf of MiMedx Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating MiMedx Group, Inc. for potential claims regarding violations of federal securities laws. The investigation follows an FDA Warning Letter informing MiMedx that its product AXIOFILL is considered a Section 351 product, implying it requires more regulatory scrutiny. As a result of this negative news, MiMedx's stock experienced a substantial decline. Investors affected by the situation are encouraged to contact the law firm for more information.
Price reaction · baseline $8.04 (2024-01-12 close) · hit after-hours · 1 other MDXG headline(s) in the window, move may be shared
day 0 close
+0.5%

Market Sentiment Analysis

CONCERNS & RISKS

  • MiMedx is under investigation for potential violations of federal securities laws.
  • The FDA has deemed MiMedx's product AXIOFILL does not meet Section 361 requirements.
  • MiMedx's stock price fell by over 10% following the announcement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~40 mo
Low dilution risk
Lead asset
Micronized DHACM
Phase 3 · Tendonitis;Achilles

Full Press Release Details

NEW YORK, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) on behalf of MiMedx stockholders. Our investigation concerns whether MiMedx has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On December 29, 2023, MiMedx issued a press release announcing that “[f]ollowing a routine inspection earlier in the year, the United States Food and Drug Administration (‘FDA’) took the position that one of the Company’s recently-launched placental-derived tissue products – AXIOFILL – does not meet the requirements as a Section 361 product and is therefore subject to enforcement as a Section 351 product. Specifically, FDA asserts that the production of AXIOFILL involves more than ‘minimal manipulation.’ The Company does not agree with FDA’s position and has been actively engaged with the agency through its ‘Request For Designation’ (‘RFD’) process. However, on December 21, 2023, MIMEDX received a Warning Letter from FDA reiterating the agency’s position on AXIOFILL.”
On this news, MiMedx’s stock price fell $0.90 per share, or 10.26%, to close at $7.87 per share on January 2, 2024.
If you purchased or otherwise acquired MiMedx shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is Bragar Eagel & Squire, P.C. investigating?

The firm is looking into potential claims against MiMedx for possible federal securities law violations.

What issue did the FDA raise regarding AXIOFILL?

The FDA stated that AXIOFILL does not meet Section 361 product requirements due to excessive manipulation.

What happened to MiMedx's stock price on January 2, 2024?

MiMedx's stock fell by $0.90, or 10.26%, closing at $7.87 per share.

How can MiMedx shareholders get involved?

Shareholders can contact Bragar Eagel & Squire for information on their rights and potential claims.

Is there a cost to participate in the investigation?

No, there is no cost or obligation for shareholders to learn more about the investigation.

Last updated: Jan 16, 2024